Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.95 |
| ▸ | LMNA | P02545 | 1/20 | 0.95 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Orotic Acid SCHEMBL23859825 | 1.00 | ALDH1A1 (0.95) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL29697185 | 1.00 | ALDH1A1 (0.95) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL28141346 | 0.98 | ALDH1A1 (0.91) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL20865 | 0.98 | ALDH1A1 (1.00) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL431534 | 0.98 | ALDH1A1 (1.00) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL29394966 | 0.98 | ALDH1A1 (1.00) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL422602 | 0.95 | ALDH1A1 (0.95) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL896844 | 0.95 | ALDH1A1 (0.95) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL122311 | 0.95 | ALDH1A1 (0.95) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL2293911 | 0.95 | ALDH1A1 (0.95) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125422-A1 | POLYMORPHIC FORMS OF CYCLO (-HIS-PRO) AND METHODS OF USE TO TREAT KIDNEY DISEASE | NOVMETAPHARMA CO., LTD. (KR) | 2026-05-07 | — | — | US | claimed |
| US-12534496-B2 | Polymorphic forms of Cyclo (-His-Pro) and methods of use to treat kidney disease | NOVMETAPHARMA CO., LTD. (KR) | 2026-01-27 | — | — | US | claimed |
| US-20260014198-A1 | Antiviral Composition for Animals | Oryx Phytochemicals LLC (US) | 2026-01-15 | — | — | US | claimed |
| US-20250387429-A1 | Nutraceutical Composition for Multimodal Prophylaxis | Cuddeback, David A (US) | 2025-12-25 | — | — | US | claimed |
| EP-4418865-B1 | LIQUID COMPOSITION CONTAINING A COMBINATION OF VITAMINS A, D, E AND K IN A LIQUID MATRIX | LIPOID GMBH (DE) | 2025-12-10 | — | — | EP | claimed |
| US-20250367099-A1 | UROLITHIN COMBINATIONS | DAMICO DAVIDE (CH) | 2025-12-04 | — | — | US | claimed |
| EP-4648749-A1 | MULTI-COMPONENT INTRAVAGINAL RING | THE POPULATION COUNCIL, INC. (US) | 2025-11-19 | — | — | EP | claimed |
| US-20250134924-A1 | Composition for Prevention and Treatment of Bacterial and Viral Infections and Inflammation | Cuddeback, David A. (US) | 2025-05-01 | — | — | US | claimed |
| CN-119859125-A | Preparation method of zinc orotate | 郑州瑞普生物工程有限公司 | 2025-04-22 | — | — | CN | claimed |
| CN-119433594-A | Lignin derived carbon-alloy-metal oxide heterojunction catalyst and preparation method thereof | 广西大学 | 2025-02-14 | — | — | CN | claimed |
| US-20050123623-A1 | Pharmaceutical compositions and their use in the treatment of neoplastic disease | CARTER JOHN (GB) | 2005-06-09 | — | — | US | claimed |
| WO-2004080417-A2 | METHODS AND COMPOSITIONS FOR BLOCKING THE CALCIUM CASCADE | GELSUS RESEARCH AND CONSULTING INC. (US) | 2004-09-23 | — | — | WO | claimed |
| US-20020193323-A1 | Compositions and methods for promoting a healthy cardiovascular system and enhancing blood flow | YEGOROVA INNA (US) | 2002-12-19 | — | — | US | claimed |
| US-20020176900-A1 | Compositions and methods for promoting a healthy cardiovascular system and enhancing blood flow | YEGOROVA INNA (US) | 2002-11-28 | — | — | US | claimed |
| WO-2000032155-A2 | SKIN CARE COMPOSITIONS CONTAINING ZINC SALTS AND RETINOIDS | JOHNSON AND JOHNSON CONSUMER COMPANIES, INC. (US) | 2000-06-08 | — | — | WO | claimed |
| WO-1997027862-A1 | SUPPLEMENTATION OF GLUCOCORTICOIDS | BELLARA MEDICAL PRODUCTS LIMITED (AU) | 1997-08-07 | — | — | WO | claimed |
| WO-1995025513-A1 | ZINC COMPOUND AND CYCLODEXTRINE FOR TREATMENT OF GASTRIC DISORDERS | BELLARA MEDICAL PRODUCTS LIMITED (AU) | 1995-09-28 | — | — | WO | claimed |
| EP-0245669-B1 | Pharmaceutical preparation for preventing damage to living cells by free radicals, or for increasing the efficacy of organic sulphur compounds, and process for increasing the life span of isolated organs | FLOERSHEIM GEORG L (CH) | 1993-12-01 | — | — | EP | claimed |
| EP-0133437-A1 | VITAMIN-CONTAINING SKIN CARE OINTMENT | ADVANCED DRUG TECHNOLOGY CORPORATION (US) | 1985-02-27 | — | — | EP | claimed |
| WO-1984002845-A1 | VITAMIN-CONTAINING SKIN CARE OINTMENT | ADVANCED DRUG TECH (US) | 1984-08-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387429-A1 | Nutraceutical Composition for Multimodal Prophylaxis | SLC39A3, SLC39A7, PLPBP | ALDH1A1 3355/4885LMNA 4804/4885CYP2C19 192/4885 |
| US-20250367099-A1 | UROLITHIN COMBINATIONS | ASAH2, HEXB, SGMS2 | ALDH1A1 1740/4885LMNA 60/4885CYP2C19 4454/4885 |
| US-20260014198-A1 | Antiviral Composition for Animals | IL17A, IRF3, NOD1 | ALDH1A1 2155/4885LMNA 1920/4885CYP2C19 147/4885 |
| US-12534496-B2 | Polymorphic forms of Cyclo (-His-Pro) and methods of use to treat kidney disease | CRH, GHRHR, CRHBP | ALDH1A1 4483/4885LMNA 3149/4885CYP2C19 320/4885 |
| US-20260125422-A1 | POLYMORPHIC FORMS OF CYCLO (-HIS-PRO) AND METHODS OF USE TO TREAT KIDNEY DISEASE | CRH, PTMS, TRHR | ALDH1A1 4575/4885LMNA 3260/4885CYP2C19 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.